POINT Biopharma Global In... (PNT)
NASDAQ: PNT
· Real-Time Price · USD
12.50
0.02 (0.16%)
At close: Dec 26, 2023, 10:00 PM
POINT Biopharma Global Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | 243.69M | 240.9M | 236.04M | 226.58M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | -9.45B | -9.45B | -9.45B | n/a | n/a | n/a | n/a | n/a | n/a | 168.31K | 168.31K |
Gross Profit | 9.69B | 9.69B | 9.68B | 226.58M | n/a | n/a | n/a | n/a | n/a | -168.31K | -168.31K |
Operating Income | 107.77M | 112.76M | 119.37M | 125.52M | -79.94M | -72.33M | -56.09M | -45.51M | -36.82M | -22.86M | -17.44M |
Interest Income | n/a | n/a | 509.7K | 557.67K | 557.67K | 557.67K | 47.97K | n/a | n/a | n/a | n/a |
Pretax Income | 127.1M | 127.17M | 129.11M | 129.59M | -78.66M | -71.86M | -56.15M | -45.6M | -37M | -23.01M | -17.46M |
Net Income | 96.55M | 97.31M | 98.14M | 98.29M | -79.17M | -72.27M | -56.5M | -45.9M | -37.26M | -23.19M | -17.57M |
Selling & General & Admin | 22.88M | 21.22M | 20.21M | 19.01M | 16.29M | 16.48M | 14.35M | 12.01M | 8.73M | 5.3M | 4.41M |
Research & Development | 113.04M | 106.92M | 96.46M | 82.05M | 63.64M | 55.85M | 41.74M | 33.51M | 28.09M | 17.57M | 13.03M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 135.92M | 128.14M | 116.67M | 101.06M | 79.94M | 72.33M | 56.09M | 45.51M | 36.82M | 22.86M | 17.44M |
Interest Expense | n/a | 1.05M | 1.56M | 1.61M | 1.65M | 604.1K | 97.27K | 52.09K | 14.69K | 11.02K | 8.15K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 135.92M | 128.14M | 116.67M | 101.06M | 79.94M | 72.33M | 56.09M | 45.51M | 36.82M | 22.86M | 17.44M |
Income Tax Expense | 30.55M | 29.86M | 30.97M | 31.29M | 512.43K | 412.97K | 353.35K | 305.66K | 259.63K | 178.58K | 113.06K |
Shares Outstanding (Basic) | 105.77M | 105.72M | 105.66M | 96.03M | 92.4M | 90.12M | 90.12M | 90.12M | 90.12M | 57.58M | 56.67M |
Shares Outstanding (Diluted) | 105.77M | 105.72M | 105.66M | 96.03M | 92.4M | 90.12M | 90.12M | 90.12M | 90.12M | 57.58M | 56.67M |
EPS (Basic) | 1.10 | 1.07 | 1.04 | 1.02 | -0.87 | -0.8 | -0.68 | -0.6 | -0.77 | -0.64 | -0.52 |
EPS (Diluted) | 1.07 | 1.04 | 1.01 | 0.99 | -0.87 | -0.8 | -0.68 | -0.6 | -0.77 | -0.64 | -0.52 |
EBITDA | 93.91M | 104.4M | 115.76M | 127.32M | -78.67M | -71.7M | -55.83M | -45.51M | -36.82M | -22.86M | -17.44M |
EBIT | -5.99B | -6.02B | -6.04B | 130.78M | -77.01M | -71.26M | -56.05M | -45.54M | -36.98M | -23M | -14.32M |
Depreciation & Amortization | -2.98M | -3.2M | -3.61M | 1.8M | 1.23M | 641.72K | 325.43K | 124.77K | 220.15K | 3.38M | 3.38M |